13 November 2025
EMADOC-1700519818-2554896
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion[1] (post authorisation)

Veyvondi

vonicog alfa

On 13 November 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Veyvondi. The marketing authorisation holder for this medicinal product is Baxalta Innovations GmbH.

The CHMP adopted an extension to an existing indication, as follows:[2]

> Prevention and treatment of haemorrhage or surgical bleeding in adults (age**d** 18 years and older) with von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contraindicated.
>
> **Treatment of haemorrhage in children (aged less than 18 years) with von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contraindicated.**
>
> VEYVONDI should not be used in the treatment of haemophilia A.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

[1] Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion
[2] New text in bold

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union